- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02095691
RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157 (RENABLATE-II)
October 30, 2015 updated by: Biosense Webster, Inc.
A Prospective, Multi-center, Non-Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II - 157)
This is a prospective, multi-center, non-randomized, feasibility study to assess the safety and effectiveness of renal artery sympathetic denervation using the investigational devices in subjects with resistant hypertension.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Prague, Czech Republic, 12808
- Charles University Hospital
-
Prague, Czech Republic, 15 030
- Na Homolce Hospital
-
-
-
-
-
Bari, Italy
- Ospedale Generale Regionale
-
-
-
-
Auckland
-
Epsom, Auckland, New Zealand
- Mercy Angiography
-
-
-
-
-
Barcelona, Spain
- Hospital Universitari Clínic de Barcelona
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject has a systolic blood pressure ≥ 140 mmHg based on an average of 3 office blood pressure readings measured according to the BP guidelines.
- Subject is adhering to a stable drug regimen of at least 3 different classes of anti-hypertensive medications, including a diuretic (with no changes for a minimum of 2 weeks prior to enrollment) at optimal dose and is expected to be maintained for at least 6 months.
- Subject is > 18 and < 85 years of age.
- Subject agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this study.
Key Exclusion Criteria:
- A secondary cause of hypertension, e.g. "white coat" hypertension (assessed by 24 h ABPM at physician's discretion), primary aldosteronism, pheochromocytoma, renal artery stenosis, drug induced-hypertension, Adult Polycystic kidney Disease, renal cell carcinoma, pyelonephritis, glomerulonephritis, coarctation of the aorta, acromegaly, Cushing's Syndrome, Conn's (primary hyperaldosteronism), polyarteritis nodosum, systemic sclerosis, parenchymal kidney disease, obstructive sleep apnoea based on a workup performed within the 12 months preceding enrollment.
- Subject has aorto-ilio-femoral artery anatomy not suitable for treatment with the investigational device(s).
- Subject has main renal arteries that are < 20 mm in length or < 4 mm in diameter.
- Subject has a prior history of any renal artery intervention including but not limited to balloon angioplasty, stenting, renal denervation or surgery.
- Subject has an estimated glomerular filtration rate (eGFR) of < 45mL/min/1.73m2, using the MDRD formula.
- Subject has type 1 diabetes mellitus.
- Subject has history of Myocardial Infarction, unstable angina pectoris, or a cerebrovascular accident in the 6 months period prior to enrolment, or documented widespread atherosclerosis, intravascular thrombosis or unstable plaques.
- Subject has hemodynamically significant valvular heart disease for which reduction of blood pressure would be considered hazardous.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Resistant Hypertension
The Celsius® ThermoCool® Renal Denervation catheter will serve to treat resistant hypertension.
|
The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure.
Time Frame: 30 days post-procedure
|
Major adverse events include Acute myocardial infarction; Death from progressive heart failure, death from aortic or peripheral artery disease, from renal failure and sudden cardiac death; New-onset heart failure; Stroke; Aortic or lower limb revascularization procedure; Lower limb amputation; Beginning dialysis; Hospital admission for hypertensive emergency unrelated to non-adherence or non-persistence with drugs at each follow up visit; Hospitalization for atrial fibrillation.
|
30 days post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Cardiovascular and Renal Events Within the 12 Month Follow-up Visit
Time Frame: 12 months post-procedure
|
These adverse events include renal artery stenosis (≥60% diameter reduction confirmed by MRI or renal angiography); peri-procedural renal artery dissection or perforation requiring intervention, serious arterial access site related complications requiring intervention or prolonging hospitalization; ≥25% reduction between baseline and 12 months in renal function measured by the estimated Glomerular Filtration Rate (eGFR), as well as composite of major adverse cardiovascular and/or renal events.
|
12 months post-procedure
|
Mean Change in Office Systolic Blood Pressure and Diastolic Blood Pressure From Baseline to 1 ,3, 6 and 12 Months Post Procedure
Time Frame: 12 months post-procedure
|
Office systolic blood pressure (SBP) and diastolic blood pressure (DBP) measures were summarized to assess the reduction in blood pressure from baseline visit to post baseline at 1, 3, 6, and 12 months.
Negative values for change represent reductions.
|
12 months post-procedure
|
Incidence of Subjects Achieving Target Systolic Blood Pressure (SBP) at 1, 3, 6 and 12 Months Post Procedure
Time Frame: 12 months post-procedure
|
The pre-specified target SBP is defined as SBP <130 mmHg.
This endpoint is defined at each of 1, 3, 6 and 12 months post procedure.
|
12 months post-procedure
|
Incidence of Subjects Achieving a ≥ 10 mmHg Reduction in Systolic Blood Pressure (SBP) at 1, 3, 6 and 12 Months Post Procedure
Time Frame: 12 months post-procedure
|
Incidence of subjects achieving a 10 mmHg or more reduction in Systolic Blood Pressure (SBP) at 1, 3, 6 and 12 months post procedure.
|
12 months post-procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
March 21, 2014
First Submitted That Met QC Criteria
March 24, 2014
First Posted (Estimate)
March 26, 2014
Study Record Updates
Last Update Posted (Estimate)
December 7, 2015
Last Update Submitted That Met QC Criteria
October 30, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RENABLATE-II
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension, Renal
-
University of AarhusOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) and other collaboratorsRecruitingHeart Failure | Percutaneous Transluminal Angioplasty | Renovascular Hypertension | Renal Artery Stenosis Atherosclerotic | Renovascular Hypertension With Renal FailureDenmark
-
Erasme University HospitalUnknownRenal Function | Resistant Hypertension | Ambulatory Blood Pressure | Renal DenervationBelgium
-
Peking University First HospitalRecruitingRenal Artery Stenosis Atherosclerotic | Secondary Hypertension Renal ArterialChina
-
Mayo ClinicUniversity of Alabama at Birmingham; University of Mississippi Medical CenterCompletedChronic Kidney Disease | Renal Artery Stenosis | Ischemic Nephropathy | Renovascular DiseaseUnited States
-
Universita di VeronaUnknownRenal Artery Obstruction | Renovascular HypertensionItaly
-
Novartis PharmaceuticalsCompletedHypertension With Renal DysfunctionJapan
-
Mayo ClinicCompletedAtherosclerotic Renal Artery Stenosis | Ischemic Nephropathy | Renovascular HypertensionUnited States
-
Peking Union Medical College HospitalNot yet recruitingDrug-eluting Balloon for Treatment of Non-atherosclerotic Renal Artery Stenosis--a Multicenter StudyHypertension, Renovascular
-
Daiichi Sankyo Co., Ltd.CompletedHypertension With Moderate Renal ImpairmentJapan
-
Medtronic EndovascularWithdrawnResistant Hypertension | Uncontrolled Hypertension | Renal Artery AblationItaly
Clinical Trials on Celsius® ThermoCool® Renal Denervation
-
InCor Heart InstituteJohnson & JohnsonUnknownHeart Failure | Chagas Cardiomyopathy | Chagas Disease | Heart Failure, SystolicBrazil
-
Biosense Webster, Inc.CompletedHypertension, RenalBelgium, Czech Republic, Italy, Australia, Denmark
-
Pamela Youde Nethersole Eastern HospitalTerminatedDiabetes Mellitus | Hypertension, Resistant | Renal Denervation TherapyHong Kong
-
Medtronic VascularCompletedUncontrolled HypertensionSpain, Australia, Germany, France, Latvia, United Kingdom, Belgium, Austria, Poland, Switzerland
-
Erasmus Medical CenterReCor Medical, Inc.Not yet recruitingHypertension | Kidney Transplantation
-
Scott Martin Miller, MDBiosense Webster, Inc.Terminated
-
Institute of Cardiology, Warsaw, PolandCompletedHypertension | Obstructive Sleep ApneaPoland
-
Oslo University HospitalUnknownHypertension, Resistant to Conventional TherapyNorway
-
Clinica MediterraneaCompletedAtrial FibrillationItaly
-
Biosense Webster, Inc.CompletedVentricular TachycardiaUnited States